TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05361291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Inferior alveolar nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Inferior alveolar nerve block
Study: NCT03447392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge Education of Chinese Medicine
Description: Discharge Education of Integrated Traditional and Western Medicine
Study: NCT04641091

Intervention type: DEVICE
Intervention: Multispectral Optoacustic Tomography (MSOT)
Description: non-invasive transcutaneous imaging of subcellular muscle components

Intervention type: DEVICE
Intervention: Multispectral Optoacustic Tomography (MSOT)
Description: non-invasive transcutaneous imaging of subcellular muscle components
Study: NCT06322134

Intervention type: OTHER
Intervention: Drowning incident
Description: Patients categorized as drowning have been experiencing respiratory impairment from submersion or immersion in liquid and needing rescue by the Royal Danish Air Force's Search and Rescue (SAR) helicopters.

Intervention type: OTHER
Intervention: Drowning incident
Description: Patients categorized as drowning have been experiencing respiratory impairment from submersion or immersion in liquid and needing rescue by the Royal Danish Air Force's Search and Rescue (SAR) helicopters.
Study: NCT03310944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT03573024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
Study: NCT05361291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Inferior alveolar nerve block
Study: NCT03801941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing ATLAS device during evaluation at 4th day
Description: Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
Study: NCT03573024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
Study: NCT04626635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7075
Description: Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7075
Description: Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
Study: NCT03885401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced care planning
Description: The intervention includes (1) screening for unhealthy behaviors, mental health needs, and social needs, (2) creation of a care plan, (3) quarterly updates to the plan, (4) a clinical navigator and community health worker to support accomplishing the care plan, (5) registry of community resources and programs, and (6) messaging and video-visit system for team members.
Study: NCT03523858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
Study: NCT02894398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
Study: NCT02412748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBTF Intervention
Description: The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Literacy Program
Description: The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
Study: NCT00130117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-metHuLeptin
Description: Starting dose: 0.08mg/kg once daily Subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Contraceptive Pills (OCPs)
Description: Sprintec taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pills (OCPs)
Description: Sprintec taken orally once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (no active medication)
Study: NCT02994173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Current clinical practice, used as a control in this study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine 0.25
Description: dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine 0.5
Description: dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine 0.75
Description: dosage
Study: NCT04222686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril Arginine
Description: 10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan Potassium
Description: 100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.
Study: NCT04237155

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will complete a verbal material scoring questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will complete a verbal material scoring questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive tests
Description: Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive tests
Description: Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
Study: NCT00995306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide (Zucapsaicin)
Description: Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide (Zucapsaicin)
Description: Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks
Study: NCT03654235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education
Description: 6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care in Primary Care Physiotherapy Units
Description: Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise
Study: NCT02047981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
Study: NCT03641703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLT180a
Description: FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
Study: NCT02488096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS-Guided Biopsy
Description: The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI + TRUS-Guided Biopsy
Description: A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy \~ 1 week after the MRI.
Study: NCT04163406

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate
Description: Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
Study: NCT02894398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
Study: NCT03669887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program
Description: The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
Study: NCT04163406

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate + GOS
Description: Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate + HMOs
Description: Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
Study: NCT05231863

Intervention type: DRUG
Intervention: TKIs
Description: tyrosine kinase inhibitors based therapy
Study: NCT04056247

Intervention type: OTHER
Intervention: Plasma sample collection
Description: Collect at least two plasma samples

Intervention type: OTHER
Intervention: Plasma sample collection
Description: Collect at least two plasma samples
Study: NCT04000555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo twice a day prescribed for the duration of antibiotics
Study: NCT01396993

Intervention type: PROCEDURE
Intervention: Breast Surgery
Description: breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps

Intervention type: PROCEDURE
Intervention: Breast Surgery
Description: Breast conserving therapy without defect correction
Study: NCT02693795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
Study: NCT04056247

Intervention type: OTHER
Intervention: Plasma sample collection
Description: Collect at least two plasma samples

Intervention type: OTHER
Intervention: Plasma sample collection
Description: Collect at least two plasma samples

Intervention type: OTHER
Intervention: Plasma sample collection
Description: Collect at least two plasma samples
Study: NCT03790748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lumbar Epidural Technique
Description: Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lumbar Epidural Technique
Description: Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25G Dural Puncture Epidural Technique
Description: 25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25G Dural Puncture Epidural Technique
Description: 25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 27G Dural Puncture Epidural Technique
Description: 27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 27G Dural Puncture Epidural Technique
Description: 27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
Study: NCT01000597

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate
Description: Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
Study: NCT05108519

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study: NCT03102320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
Study: NCT04443114

Intervention type: OTHER
Group type: OTHER
Intervention: Organ Donation Workshop
Description: Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators

Intervention type: OTHER
Group type: OTHER
Intervention: Organ Donation Workshop
Description: Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators

Intervention type: OTHER
Group type: OTHER
Intervention: End of Life Care Workshop
Description: Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
Study: NCT03102320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
Study: NCT04443114

Intervention type: OTHER
Group type: OTHER
Intervention: End of Life Care Workshop
Description: Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
Study: NCT01457001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25-OH-D vitamin
Study: NCT02745236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner Led-Care
Description: Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiologist Led-Care
Description: Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
Study: NCT03615911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine candidate MVA-MERS-S
Description: vaccination with MVA-MERS-S in two escalating dose regimes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine candidate MVA-MERS-S
Description: vaccination with MVA-MERS-S in two escalating dose regimes
Study: NCT03303092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125
Description: TEV-48125 will be subcutaneously administered once monthly for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 or placebo
Description: TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be subcutaneously administered once monthly for 3 months.
Study: NCT01571648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
Study: NCT02589795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-C CN54ENV
Description: DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-C CN54ENV
Description: DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-C CN54ENV
Description: DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140
Description: Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140
Description: Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140
Description: Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigrid Delivery System - Intramuscular
Description: Electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigrid Delivery System - Intramuscular
Description: Electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigrid Delivery System - Intradermal
Description: Electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigrid Delivery System - Intradermal
Description: Electroporation